Similar companies
Income Statement (NONE)
| Q1 '25 | QoQ | |
|---|---|---|
| Revenue | 121M | 2.3% |
| Gross Profit | 112M | 3.2% |
| Cost of Revenue | 9.8M | 6.9% |
| Operating expense | 169M | 7% |
| Net Income | -59M | 20.7% |
| EBITDA | -57M | 19.2% |
Balance Sheet (NONE)
| Q1 '25 | QoQ | |
|---|---|---|
| Total Assets | 597M | 5% |
| Total Liabilities | 543M | 6.3% |
| Total Equity | 53M | 6.7% |
| Shares Outstanding | 49M | 0.7% |
Cash Flow (NONE)
| Q1 '25 | QoQ | |
|---|---|---|
| Cash from operations | -43M | 65.5% |
| Cash from financing | 29M | 105.5% |
EPS
Financial Highlights for Axsome Therapeutics in Q1 '25
Axsome Therapeutics reported a revenue of 121M, which is a 2.3% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 112M, marking a 3.2% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 9.8M, a -6.9% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 169M, showing a -7% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -59M, showing a 20.7% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -57M, showing a 19.2% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Axsome Therapeutics with growth in revenue, gross profit, and net income.
